β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

• US 9,828,410 B2
• Filed: 03/07/2016
• Issued: 11/28/2017
• Est. Priority Date: 03/06/2015
• Status: Active Grant

• Current Assignee: Atea Pharmaceuticals, Inc.
• Original Assignee: Atea Pharmaceuticals, Inc.
• Inventors: Sommadossi, Jean-Pierre, Moussa, Adel
• Primary Examiner(s): McIntosh, III, Traviss C
• Application Number:
  US15/063,461
• Publication Number:
  US 20160257706A1
• Time in Patent Office: 631 Days
• Field of Search: None
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07H 19/16 Purine radicals
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/207 the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Abstract

A compound of the structure:

or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims

1. A compound of the formula:

2. The compound of claim 1 of the formula

3. The compound of claim 1 of the formula